The DOI matches its Crossref record.
In vivo targeting of SF/HGF and c‐met expression via U1snRNA/ribozymes inhibits glioma growth and angiogenesis and promotes apoptosis
Abstract
The multifunctional growth factor scatter factor/hepatocyte growth factor (SF/HGF) and its receptor c‐met have been implicated in the genesis, malignant progression, and chemo/radioresistance of multiple human malignancies, including gliomas. We examined the antitumor effects of targeting SF/HGF and c‐met expression in pre‐established glioma xenografts by using novel chimeric U1snRNA/ribozymes. Transient expression of anti‐SF/HGF and anti‐c‐met U1snRNA/ribozymes inhibited SF/HGF and c‐met expression, c‐met receptor activation, tumor cell migration, and anchorage‐independent colony formation in vitro. Delivery of U1snRNA/ribozymes to established subcutaneous glioma xenografts via liposome‐DNA complexes significantly inhibited tumor growth as well as tumor SF/HGF and c‐met expression levels. Histologic analysis of tumors treated with U1snRNA/ribozymes showed a significant decrease in blood vessel density, an increase in activation of the pro‐apoptotic enzyme caspase‐3, and an increase in tumor cell apoptosis. Treatment of animals bearing intracranial glioma xenografts with anti‐SF/HGF and anti‐c‐met U1snRNA/ribozymes by either intratumoral injections of adenoviruses expressing the transgenes or intravenous injections of U1snRNA/ribozyme‐liposome complexes substantially inhibited tumor growth and promoted animal survival. We demonstrate that SF/HGF and/or c‐met expression can be targeted in vivo to inhibit tumor growth. In addition, our findings represent the first in vivo application of chimeric U1snRNA/ribozymes, which have numerous potential therapeutic gene‐targeting applications.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Met, metastasis, motility and more
Birchmeier, C., Birchmeier, W., Gherardi, E., & Vande Woude, G. F. (2003) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1261 · Cited by 2,602
Yakes, F. M., Chen, J., Tan, J., Yamaguchi, K., Shi, Y., Yu, P., Qian, F., Chu, F., Bentzien, F., Cancilla, B., et al. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0264 · Cited by 1,336
Scatter-factor and semaphorin receptors: cell signalling for invasive growth
Trusolino, L., & Comoglio, P. M. (2002) · Nature Reviews Cancer · doi:10.1038/nrc779 · Cited by 745
c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention
Christensen, J. G., Burrows, J., & Salgia, R. (2005) · Cancer Letters · doi:10.1016/j.canlet.2004.09.044 · Cited by 513
Vieira, D., & Gamarra, L. (2016) · International Journal of Nanomedicine · doi:10.2147/ijn.s117210 · Cited by 427
Metadata
- Authors
- Abounader, R., Lal, B., Luddy, C., Koe, G., Davidson, B., Rosen, E. M., & Laterra, J.
- Venue
- The FASEB Journal
- Publisher
- Wiley
- Published
- 2001-11-29
- Volume
- 16
- Issue
- 1
- Pages
- 1-16
- ISSN
- 0892-6638 (ISSN-L)
- 1530-6860
- OpenAlex
- W2126890008
- Cited by
- 186
- References
- 0
- FWCI
- 3.91
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: In vivo targeting of SF/HGF and c‐met expression via U1snRNA/ribozymes inhibits glioma growth and angiogenesis and promotes apoptosis. https://app.cochat.ai/papers/10.1096/fj.01-0421fje
- The paper
- Abounader, R., Lal, B., Luddy, C., Koe, G., Davidson, B., Rosen, E. M., & Laterra, J. (2002). In vivo targeting of SF/HGF and c‐met expression via U1snRNA/ribozymes inhibits glioma growth and angiogenesis and promotes apoptosis. The FASEB Journal. https://doi.org/10.1096/fj.01-0421fje
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.